Quality Issues Lead to Shuttering of Teva’s Hungarian Plant

Drug GMP Report
A A
Teva is expected to close its facility outside Budapest, Hungary, following a string of quality control problems and major recalls.

To View This Article:

Login

Subscribe To Drug GMP Report